Clinical trial · Interventional
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.
NCT03647072CI-TRIAL-00034569recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CHOP | Drug | — | UNRESOLVED |
| CHOP Plus Famotidine | Drug | — | UNRESOLVED |
| CHOP Plus Lanzoprazole | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- CHOP
- description
- CHOP only
- interventionNames
- Drug: CHOP
- type
- ACTIVE_COMPARATOR
- label
- CHOP Plus Lanzoprazole
- description
- CHOP Plus Lanzoprazole 60 mg
- interventionNames
- Drug: CHOP Plus Lanzoprazole
- type
- ACTIVE_COMPARATOR
- label
- CHOP Plus Famotidine
- description
- CHOP Plus Famotidine 40 mg
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * DLBCL Lymphoma subtype --No comorbid disease Exclusion Criteria: * Pregnancy * Peptic ulcer * Severe cardiac disease * Osteoporosis
References
Publications (1)
- DERIVEDHegazy SK, El-Haggar SM, Alhassanin SA, El-Berri EI. Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma. Med Oncol. 2021 Jan 4;38(1):4. doi: 10.1007/s12032-020-01452-z. PMID 33394214